Los Angeles Capital Management LLC Acquires 638 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Los Angeles Capital Management LLC boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 9.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,371 shares of the biopharmaceutical company’s stock after acquiring an additional 638 shares during the period. Los Angeles Capital Management LLC’s holdings in Celldex Therapeutics were worth $273,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Arizona State Retirement System grew its holdings in Celldex Therapeutics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock worth $601,000 after acquiring an additional 325 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 955 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Celldex Therapeutics by 10.0% during the 1st quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock worth $552,000 after acquiring an additional 1,194 shares in the last quarter. Fisher Asset Management LLC grew its holdings in Celldex Therapeutics by 6.2% during the 4th quarter. Fisher Asset Management LLC now owns 21,812 shares of the biopharmaceutical company’s stock worth $865,000 after acquiring an additional 1,274 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in Celldex Therapeutics by 34.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,582 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 9th. Wells Fargo & Company raised their price target on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Wolfe Research assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $63.83.

Celldex Therapeutics Stock Up 5.8 %

Shares of Celldex Therapeutics stock opened at $44.16 on Monday. The firm has a market capitalization of $2.93 billion, a P/E ratio of -15.49 and a beta of 1.56. The company has a 50 day moving average price of $38.14 and a 200 day moving average price of $38.87. Celldex Therapeutics, Inc. has a 52 week low of $22.11 and a 52 week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. The firm had revenue of $2.50 million during the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. As a group, research analysts anticipate that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.